Specificity and sensitivity of magnetic resonance imaging findings in the diagnosis of progressive supranuclear palsy
Corresponding Author
Stephen Bacchi
University of Adelaide, Adelaide, South Australia, Australia
Correspondence
Mr Stephen Bacchi, Medical School, University of Adelaide, North terrace Adelaide, SA 5005, Australia.
Email: [email protected]
Search for more papers by this authorIvana Chim
University of Adelaide, Adelaide, South Australia, Australia
Search for more papers by this authorSandy Patel
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Search for more papers by this authorCorresponding Author
Stephen Bacchi
University of Adelaide, Adelaide, South Australia, Australia
Correspondence
Mr Stephen Bacchi, Medical School, University of Adelaide, North terrace Adelaide, SA 5005, Australia.
Email: [email protected]
Search for more papers by this authorIvana Chim
University of Adelaide, Adelaide, South Australia, Australia
Search for more papers by this authorSandy Patel
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Search for more papers by this authorSummary
Progressive supranuclear palsy (PSP) is a neurodegenerative condition that can only be diagnosed conclusively on pathological examination. Currently, the diagnosis is based upon the National Institute of Neurological Disorders and Stroke and the Society for PSP criteria. These criteria consist of purely clinical findings. Elements of brain MRI that are being investigated for this role include identifying structural features on conventional MRI, volume changes, signal abnormalities and diffusion changes. The aim of this study is to conduct a systematic search to identify which MRI findings have evidence to support their sensitivity/specificity/accuracy in the diagnosis of PSP. A search was conducted of Pubmed and Medline on July 5th–6th 2016 using the medical subject headings progressive supranuclear palsy and MRI. Seventy articles were identified which assessed the sensitivity/specificity/accuracy of MRI signs for the diagnosis of PSP. There were 13 studies that identified MRI features that had ≥95% sensitivity and specificity for the diagnosis of PSP. Four of these studies identified the magnetic resonance parkinsonism index as highly sensitive and specific. There were only four studies which assessed how effective given MRI features are at predicting the pathological diagnosis of PSP. Several markers, such as the magnetic resonance parkinsonism index, have been demonstrated to be both specific and sensitive for PSP. However, many studies assessing these markers have common weaknesses including small sample size and lacking autopsy correlation.
References
- 1Williams D, Lees A. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8: 270–9.
- 2Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop. Neurology 1996; 47: 1–9.
- 3Litvan I. Diagnosis and management of progressive supranuclear palsy. Semin Neurol 2001; 21: 41–8.
- 4Lopez OL, Litvan I, Catt KE, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999; 53: 1292–9.
- 5Verma R, Gupta M. Hummingbird sign in progressive supranuclear palsy. Ann Saudi Med 2012; 32: 663–4.
- 6Mudali D, Teune LK, Renken RJ, Leenders KL, Roerdink JB. Classification of Parkinsonian syndromes from FDG-PET brain data using decision trees with SSM/PCA features. Computat Mathemat Methods Med 2015; 2015: 136921.
- 7Piattella MC, Tona F, Bologna M, et al. Disrupted resting-state functional connectivity in progressive supranuclear palsy. AJNR 2015; 36: 915–21.
- 8Hutchinson M, Raff U, Chaná P, Huete I. Spin-lattice distribution MRI maps nigral pathology in progressive supranuclear palsy (PSP) during Life: a pilot study. PLoS One 2014; 9: e85194.
- 9Han YH, Lee JH, Kang BM, et al. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy. J Neurol Sci 2013; 325: 29–35.
- 10Adachi M, Kawanami T, Ohshima F, Kato T. Upper midbrain profile sign and cingulate sulcus sign: MRI findings on sagittal images in idiopathic normal-pressure hydrocephalus, Alzheimer's disease, and progressive supranuclear palsy. Radiat Med 2006; 24: 568–72.
- 11Adachi M, Kawanami T, Ohshima H, Sugai Y, Hosoya T. Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magnetic Resonan Med Sci 2004; 3: 125–32.
- 12Asato R, Akiguchi I, Masunaga S, Hashimoto N. Magnetic resonance imaging distinguishes progressive supranuclear palsy from multiple system atrophy. J Neural Transm 2000; 107: 1427–36.
- 13Barsottini OG, Ferraz HB, Maia AC Jr, Silva CJ, Rocha AJ. Differentiation of Parkinson's disease and progressive supranuclear palsy with magnetic resonance imaging: the first Brazilian experience. Parkinsonism Relat Disord 2007; 13: 389–93.
- 14Borroni B, Malinverno M, Gardoni F, et al. A combination of CSF tau ratio and midsaggital midbrain-to-pons atrophy for the early diagnosis of progressive supranuclear palsy. J Alzheimer's Dis 2010; 22: 195–203.
- 15Calabrese M, Gajofatto A, Gobbin F, et al. Late-onset multiple sclerosis presenting with cognitive dysfunction and severe cortical/infratentorial atrophy. Multiple Scler J 2014; 21: 580–9.
- 16Cosottini M, Ceravolo R, Faggioni L, et al. Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurol Scand 2007; 116: 37–42.
- 17Gama R, Távora D, Bomfim R, Silva C, Bruin V, Bruin P. Morphometry MRI in the differential diagnosis of parkinsonian syndrome. Arq Neuropsiquiatr 2010; 68: 333–8.
- 18Hussl A, Mahlknecht P, Scherfler C, et al. Diagnostic accuracy of the magnetic resonance parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. Mov Disord 2010; 25: 2444–9.
- 19Ito S, Shirai W, Hattori T. Putaminal hyperintensity on T1-weighted MR imaging in patients with the Parkinson variant of multiple system atrophy. AJNR 2009; 30: 689–92.
- 20Kaasinen V, Kangassalo N, Gardberg M, et al. Midbrain-to-pons ratio in autopsy-confirmed progressive supranuclear palsy: replication in an independent cohort. Neurol Sci 2015; 36: 1251–3.
- 21Kataoka H, Tonomura Y, Taoka T, Ueno S. Signal changes of superior cerebellar peduncle on fluid-attenuated inversion recovery in progressive supranuclear palsy. Parkinsonism Relat Disord 2008; 14: 63–5.
- 22Kim YE, Kang SY, Ma HI, Ju YS, Kim YJ. A visual rating scale for the hummingbird sign with adjustable diagnostic validity. J Parkinsons Dis 2015; 5: 605–12.
- 23Kim YH, Ma HI, Kim YJ. Utility of the midbrain tegmentum diameter in the differential diagnosis of progressive supranuclear palsy from idiopathic Parkinson's disease. J Clin Neurol 2015; 11: 268–74.
- 24Kurata T, Kametaka S, Ohta Y, et al. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage. Intern Med 2011; 50: 2775–81.
- 25Longoni G, Agosta F, Kostic VS, et al. MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease. Move Disord 2011; 26: 247–55.
- 26Looi JC, Macfarlane MD, Walterfang M, et al. Morphometric analysis of subcortical structures in progressive supranuclear palsy: in vivo evidence of neostriatal and mesencephalic atrophy. Psychiatry Res 2011; 194: 163–75.
- 27Massey LA, Micallef C, Paviour DC, et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Move Disord 2012; 27: 1754–62.
- 28Massey L, Jäger H, Paviour D, et al. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology 2013; 80: 1856–61.
- 29Meijer FJ, van Rumund A, Tuladhar AM, et al. Conventional 3T brain MRI and diffusion tensor imaging in the diagnostic workup of early stage parkinsonism. Neuroradiology 2015; 57: 655–69.
- 30Morelli M, Arabia G, Novellino F, et al. MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study. Neurology 2011; 77: 1042–7.
- 31Morelli M, Arabia G, Salsone M, et al. Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease. Move Disord 2011; 26: 527–33.
- 32Mostile G, Nicoletti A, Cicero CE, et al. Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism. Neurol Sci 2016; 37: 591–5.
- 33Nicoletti G, Tonon C, Lodi R, et al. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. Move Disord 2008; 23: 2370–6.
- 34Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005; 64: 2050–5.
- 35Owens E, Krecke K, Ahlskog JE, et al. Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy. Parkinsonism Relat Disord 2016; 28: 107–11.
- 36Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Neuroradiology 2008; 246: 214–21.
- 37Righini A, Antonini A, De Notaris R, et al. MR imaging of the superior profile of the midbrain: differential diagnosis between progressive supranuclear palsy and Parkinson disease. Am J Neuroradiol 2004; 25: 927–32.
- 38Rizzo G, Martinelli P, Manners D, et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 2008; 131: 2690–700.
- 39Sankhla CS, Patil KB, Sawant N, Gupta S. Diagnostic accuracy of Magnetic Resonance Parkinsonism Index in differentiating progressive supranuclear palsy from Parkinson's disease and controls in Indian patients. Neurol India 2016; 64: 239–45.
- 40Schrag A, Good C, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000; 54: 697–702.
- 41Soliveri P, Monza D, Paridi D, et al. Cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy. Neurology 1999; 53: 502–7.
- 42Wadia P, Howard P, Ribeirro M, et al. The value of GRE, ADC and routine MRI in distinguishing Parkinsonian disorders. Canad J Neurol Sci 2013; 40: 389–402.
- 43Whitwell JL, Jack CR Jr, Parisi JE, et al. Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. Europ J Neurol 2013; 20: 1417–22.
- 44Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD. J Neural Transm (Vienna) 2003; 110: 151–69.
- 45Zanigni S, Calandra-Buonaura G, Manners DN, et al. Accuracy of MR markers for differentiating progressive supranuclear Palsy from Parkinson's disease. Neuroimage Clin 2016; 11: 736–42.
- 46Baudrexel S, Seifried C, Penndorf B, et al. The value of putaminal diffusion imaging versus 18-fluorodeoxyglucose positron emission tomography for the differential diagnosis of the Parkinson variant of multiple system atrophy. Move Disord 2014; 29: 380–7.
- 47Boxer A, Geschwind M, Belfor N, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006; 63: 81–6.
- 48Cherubini A, Morelli M, Nistico R, et al. Magnetic resonance support vector machine discriminates between Parkinson disease and progressive supranuclear palsy. Move Disord 2014; 29: 266–9.
- 49Cordato N, Pantelis C, Halliday G, et al. Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 2002; 125: 789–800.
- 50Focke NK, Helms G, Scheewe S, et al. Individual voxel-based subtype prediction can differentiate progressive supranuclear palsy from idiopathic Parkinson syndrome and healthy controls. Hum Brain Mapp 2011; 32: 1905–15.
- 51Groschel K, Hauser TK, Luft A, et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. NeuroImage 2004; 21: 714–24.
- 52Paviour D, Price S, Stevens J, Lees A, Fox N. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2005; 64: 675–9.
- 53Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC. Regional brain volumes distinguish PSP, MSA-P, and PD: MRI-based clinico-radiological correlations. Move Disord 2006; 21: 989–96.
- 54Price S, Paviour D, Scahill R, et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. NeuroImage 2004; 23: 663–9.
- 55Sakurai K, Imabayashi E, Tokumaru AM, et al. The feasibility of white matter volume reduction analysis using SPM8 plus DARTEL for the diagnosis of patients with clinically diagnosed corticobasal syndrome and Richardson's syndrome. Neuroimage Clin 2015; 7: 605–10.
- 56Scherfler C, Göbel G, Müller C, et al. Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. Neurology 2016; 86: 1242–9.
- 57Schulz J, Skalej M, Wedekind D, et al. Magnetic resonance imaging–based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999; 45: 65–74.
- 58Arabia G, Morelli M, Paglionico S, et al. An magnetic resonance imaging T2*-weighted sequence at short echo time to detect putaminal hypointensity in Parkinsonisms. Move Disord 2010; 25: 2728–34.
- 59Bae YJ, Kim JM, Kim E, et al. Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: comparison with (123) I-FP-CIT SPECT. Move Disord 2016; 31: 684–92.
- 60Gupta D, Saini J, Kesavadas C, Sarma PS, Kishore A. Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 2010; 52: 1087–94.
- 61Hara K, Watanabe H, Ito M, et al. Potential of a new MRI for visualizing cerebellar involvement in progressive supranuclear palsy. Parkinsonism Relat Disord 2014; 20: 157–61.
- 62Kraft E, Schwarz J, Trenkwalder C, Vogl T, Pfluger T, Oertel W. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 1999; 56: 225–8.
- 63Reiter E, Mueller C, Pinter B, et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Move Disord 2015; 30: 1068–76.
- 64Sakurai K, Imabayashi E, Tokumaru AM, et al. Volume of interest analysis of spatially normalized PRESTO imaging to differentiate between Parkinson disease and atypical Parkinsonian syndrome. Magnetic Res Med Sci 2017; 16: 16–22.
- 65Sawa N, Kataoka H, Kiriyama T, et al. Cerebellar dentate nucleus in progressive supranuclear palsy. Clin Neurol Neurosurg 2014; 118: 32–6.
- 66Ito S, Makino T, Shirai W, Hattori T. Diffusion tensor analysis of corpus callosum in progressive supranuclear palsy. Neuroradiology 2008; 50: 981–5.
- 67Knake S, Belke M, Menzler K, et al. In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS. Move Disord 2010; 25: 1232–8.
- 68Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006; 129: 2679–87.
- 69Paviour DC, Thornton JS, Lees AJ, Jager HR. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy. Move Disord 2007; 22: 68–74.
- 70Planetta PJ, Ofori E, Pasternak O, et al. Free-water imaging in Parkinson's disease and atypical parkinsonism. Brain 2016; 139: 495–508.
- 71Seppi K, Schocke M, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003; 60: 922–7.
- 72Surova Y, Nilsson M, Latt J, et al. Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. Neuroradiology 2015; 57: 1079–91.
- 73Boelmans K, Holst B, Hackius M, et al. Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy. Move Disord 2012; 27: 421–7.
- 74Forkert N, Schmidt-Richberg A, Holst B, Münchau A, Handels H, Boelmans K. Image-based Classification of Parkinsonian syndromes using T2’-Atlases. Stud Health Technol Inform 2011; 169: 465–9.
- 75Fukui Y, Hishikawa N, Sato K, et al. Differentiating progressive supranuclear palsy from Parkinson's disease by MRI-based dynamic cerebrospinal fluid flow. J Neurol Sci 2015; 357: 178–82.
- 76Marquand AF, Filippone M, Ashburner J, et al. Automated, high accuracy classification of Parkinsonian disorders: a pattern recognition approach. PLoS One 2013; 8: e69237.
- 77Ohtsuka C, Sasaki M, Konno K, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 2014; 20: 755–60.
- 78Salvatore C, Cerasa A, Castiglioni I, et al. Machine learning on brain MRI data for differential diagnosis of Parkinson's disease and progressive supranuclear palsy. J Neurosci Methods 2014; 222: 230–7.
- 79Eckert T, Sailer M, Kaufmann J, et al. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. NeuroImage 2004; 21: 229–35.
- 80Osaki Y, Ben-Shlomo Y, Lees AJ, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Move Disord 2004; 19: 181–9.